FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

被引：0

作者：

Moore, K. ^{[1
]}

Oza, A. ^{[2
]}

Colombo, N. ^{[3
,4
]}

Oaknin, A. ^{[5
]}

Scambia, G. ^{[6
]}

Lorusso, D. ^{[7
]}

Farias-Eisner, R. ^{[8
]}

Banerjee, S. ^{[9
]}

Murphy, C. ^{[10
]}

Tanyi, J. ^{[11
]}

Hirte, H. ^{[12
]}

Konner, J. ^{[13
]}

Lim, P. ^{[14
]}

Hayes, M. Prasad ^{[15
]}

Monk, B. ^{[16
]}

Kim, S. ^{[17
]}

Wang, J. ^{[18
]}

Pautier, P. ^{[19
]}

Vergote, I. ^{[20
]}

Birrer, M. ^{[21
]}

机构：

[1] Univ Oklahoma, Dept Obstet & Gynecol Univ, Stephenson Canc Ctr, Oklahoma City, OK USA

[2] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[3] European Inst Oncol, Dept Gynecol Oncol, Milan, Italy

[4] Univ Milano Bicocca, Milan, Italy

[5] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain

[6] Univ Cattolica, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

[7] Fdn IRCCS Ist Nazl Tumori, Gynecol Oncol, Milan, Italy

[8] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA

[9] Royal Marsden Hosp NHS Fdn Trust, Gynaecol, London, England

[10] Bon Secours Hosp, Med Oncol, Cork, Ireland

[11] Univ Penn, Obstet & Gynecol, Philadelphia, PA 19104 USA

[12] Juravinski Canc Ctr, Oncol, Hamilton, ON, Canada

[13] Mem Sloan Kettering Canc Ctr, Gynecol Oncol, 1275 York Ave, New York, NY 10021 USA

[14] Ctr Hope, Gynecol Oncol, Reno, NV USA

[15] Icahn Sch Med Mt Sinai, Obstet & Gynecol, New York, NY 10029 USA

[16] Creighton Univ, Univ Arizona, St Josephs Hosp, Gynecol Oncol,Arizona Oncol,Coll Med,Sch Med, Phoenix, AZ USA

[17] Univ Texas Houston, McGovern Med Sch, Houston, TX USA

[18] ImmunoGen Inc, Clin Dev, Waltham, MA USA

[19] Gustave Roussy, Med, Villejuif, France

[20] Univ Hosp Leuven Campus Gasthuisberg, Gynaecol, Leuven, Belgium

[21] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, MA USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

992O

引用

页数：1

共 50 条

[21] Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. [J].

Moore, Kathleen N. ;

Martin, Lainie P. ;

Seward, Shelly Marie ;

Bauer, Todd Michael ;

O'Malley, David M. ;

Perez, Raymond P. ;

Oza, Amit M. ;

Jeong, Woondong ;

Kirby, Maurice William ;

Zhou, Yinghui ;

Michenzie, Mary F. ;

Ponte, Joseph ;

Ruiz-Soto, Rodrigo ;

Birrer, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[22] Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011) [J].

Moore, K. N. ;

Oza, A. M. ;

Colombo, N. ;

Oaknin, A. ;

Scambia, G. ;

Lorusso, D. ;

Banerjee, S. ;

Murphy, C. ;

Konner, J. ;

Lim, P. ;

Prasad-Hayes, M. ;

Monk, B. J. ;

Wang, J. ;

Birrer, M. J. ;

Vergote, I. B. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S790-S791

[23] Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer [J].

Moore, Kathleen N. ;

O'Malley, David M. ;

Vergote, Ignace ;

Martin, Lainie P. ;

Gonzalez-Martin, Antonio ;

Malek, Karim ;

Birrer, Michael J. .

GYNECOLOGIC ONCOLOGY, 2018, 151 (01) :46-52

[24] FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer. [J].

Moore, Kathleen N. ;

Vergote, Ignace ;

Oaknin, Ana ;

Colombo, Nicoletta ;

Banerjee, Susana N. ;

Oza, Amit M. ;

Pautier, Patricia ;

Kelly, Catherine Margaret ;

Malek, Karim S. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[25] FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer [J].

Moore, K. N. ;

Vergote, I. ;

Oaknin, A. ;

Colombo, N. ;

Banerjee, S. ;

Oza, A. M. ;

Pautier, P. ;

Kelly, C. M. ;

Malek, K. ;

Birrer, M. J. .

ANNALS OF ONCOLOGY, 2017, 28

[26] Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study [J].

Matulonis, Ursula A. A. ;

Lorusso, Domenica ;

Oaknin, Ana ;

Pignata, Sandro ;

Dean, Andrew ;

Denys, Hannelore ;

Colombo, Nicoletta ;

Van Gorp, Toon ;

Konner, Jason A. A. ;

Marin, Margarita Romeo ;

Harter, Philipp ;

Murphy, Conleth G. G. ;

Wang, Jiuzhou ;

Noble, Elizabeth ;

Esteves, Brooke ;

Method, Michael ;

Coleman, Robert L. L. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13) :2436-+

[27] Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study [J].

Matulonis, Ursula A. ;

Lorusso, Domenica ;

Oaknin, Ana ;

Pignata, Sandro ;

Dean, Andrew ;

Denys, Hannelore ;

Colombo, Nicoletta ;

Van Gorp, Toon ;

Konner, Jason A. ;

Marin, Margarita Romeo ;

Harter, Philipp ;

Murphy, Conleth G. ;

Wang, Jiuzhou ;

Noble, Elizabeth ;

Esteves, Brooke ;

Method, Michael ;

Coleman, Robert L. .

OBSTETRICAL & GYNECOLOGICAL SURVEY, 2023, 78 (06) :343-344

[28] Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite [J].

Tu, Ya-Ping ;

Hanze, Eva ;

Zhu, Fengying ;

Lagraauw, H. Maxime ;

Sloss, Callum M. ;

Method, Michael ;

Esteves, Brooke ;

Westin, Eric H. ;

Berkenblit, Anna .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (02) :568-581

[29] Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study [J].

Matulonis, Ursula ;

Lorusso, Domenica ;

Oaknin, Ana ;

Pignata, Sandro ;

Denys, Hannelore ;

Colombo, Nicoletta ;

Van Gorp, Toon ;

Konner, Jason ;

Romeo Marin, Margarita ;

Harter, Philipp ;

Murphy, Conleth ;

Wang, Jiuzhou ;

Noble, Elizabeth ;

Esteves, Brooke ;

Method, Michael ;

Coleman, Robert .

GYNECOLOGIC ONCOLOGY, 2022, 166 :S50-S50

[30] Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine [J].

Martin, Lainie P. ;

Konner, Jason A. ;

Moore, Kathleen N. ;

Seward, Shelly M. ;

Matulonis, Ursula A. ;

Perez, Raymond P. ;

Su, Ying ;

Berkenblit, Anna ;

Ruiz-Soto, Rodrigo ;

Birrer, Michael J. .

GYNECOLOGIC ONCOLOGY, 2017, 147 (02) :402-407

← 1 2 3 4 5 →